{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:59:09Z","timestamp":1791460749738,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.clinthera.2016.04.037","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T07:07:46Z","timestamp":1463814466000},"page":"1288-1298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct01032629","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01730534","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Guntram","family":"Schernthaner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Helene","family":"Schernthaner-Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerit-Holger","family":"Schernthaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.04.037_bib1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.04.037_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","article-title":"Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored","volume":"2","author":"McMurray","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib7","series-title":"Diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes","year":"2008"},{"key":"10.1016\/j.clinthera.2016.04.037_bib8","series-title":"European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus","year":"2012"},{"key":"10.1016\/j.clinthera.2016.04.037_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.04.037_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib11","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib14","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","article-title":"Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study","volume":"380","author":"Tonelli","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.04.037_bib17","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.04.037_bib18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2016.04.037_bib20","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib21","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib22","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-010-1864-z","article-title":"Intensified glucose lowering in type 2 diabetes: time for a reappraisal","volume":"53","author":"Yudkin","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2016.04.037_bib23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.04.037_bib25","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.2337\/dc11-s246","article-title":"Diuretic treatment of hypertension","volume":"34","author":"Grossman","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.HYP.17.1.15","article-title":"Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus","volume":"17","author":"Klauser","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.clinthera.2016.04.037_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib28","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S2213-8587(15)00426-X","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Ceriello","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2016.04.037_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2016.04.037_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.39.1.38","article-title":"Hemodynamic effects of glucagon in patients with heart disease","volume":"39","author":"Williams","year":"1969","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.04.037_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/01.CIR.42.1.53","article-title":"Effects of glucagon on myocardial metabolism in patients with and without coronary artery disease","volume":"42","author":"Bourassa","year":"1970","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.04.037_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib35","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-010-1702-3","article-title":"Is the ADA\/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis","volume":"53","author":"Schernthaner","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2016.04.037_bib36","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2016.04.037_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/dom.12281","article-title":"Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment","volume":"16","author":"Groop","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/dom.12321","article-title":"Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged \u2265 65 years","volume":"16","author":"Schernthaner","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-154-10-201105170-00007","article-title":"Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis","volume":"154","author":"Gross","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib41","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","article-title":"Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients","volume":"14","author":"Esposito","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib42","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s00059-016-4427-3","article-title":"Glucose lowering therapy in type 2 diabetes: New hope after EMPA-REG OUTCOME trial","volume":"41","author":"Schernthaner","year":"2016","journal-title":"HERZ"},{"key":"10.1016\/j.clinthera.2016.04.037_bib43","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macro Vascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.04.037_bib45","doi-asserted-by":"crossref","first-page":":S155","DOI":"10.2337\/dcS13-2031","article-title":"Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib46","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib47","first-page":"346","article-title":"Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus","volume":"12","author":"Prager","year":"1986","journal-title":"Diabete Metab"},{"key":"10.1016\/j.clinthera.2016.04.037_bib48","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2016.04.037_bib49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2016.04.037_bib50","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib51","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrendo.2015.132","article-title":"Risk of metformin use in patients with T2DM and advanced CKD","volume":"11","author":"Schernthaner","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl B1","key":"10.1016\/j.clinthera.2016.04.037_bib52","first-page":"113","article-title":"Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease","volume":"26","author":"Wanner","year":"2015","journal-title":"JASN"},{"key":"10.1016\/j.clinthera.2016.04.037_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1681\/ASN.2007060678","article-title":"Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease","volume":"19","author":"Schneider","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2016.04.037_bib54","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.04.037_bib55","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jchf.2014.04.005","article-title":"Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study","volume":"2","author":"Weir","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2016.04.037_bib56","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.04.037_bib57","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-0764","article-title":"Association between hospitalization for heart failure and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: an observational study","author":"Fu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib58","doi-asserted-by":"crossref","DOI":"10.2337\/dcS15-3009","article-title":"Is the use of DPP-4 inhibitors associated with an increased risk for heart failure\u2014lessons from SAVOR, EXAMINE and TECOS","author":"Schernthaner","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2016.04.037_bib59","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJMoa1506115","article-title":"A multicenter observational study of incretin-based drugs and heart failure","volume":"374","author":"Filion","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.04.037_bib60","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm486096.htm. Accessed 13.5.2016, 13:41."},{"key":"10.1016\/j.clinthera.2016.04.037_bib61","unstructured":"Diabetes in Control. Victoza LEADER Trial Top-Line Results Announced. http:\/\/www.diabetesincontrol.com\/victoza-leader-trial-top-line-results-announced\/. Accessed 13.5.2016, 13:42."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T05:02:44Z","timestamp":1656478964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816303022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0149291816303022"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.04.037","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}